TKT Hopes To "Break Even" In 2006 Following Hunter Syndrome Therapy BLA
This article was originally published in The Pink Sheet Daily
Executive Summary
The company is "refocusing" on lysosomal storage disease therapies, with a BLA for Hunter syndrome agent I2S expected in 2005, CEO Astrue tells BIO.